Botox Application's Moment Of Truth May Come Before Off-Label Showdown
This article was originally published in The Pink Sheet Daily
Executive Summary
In an unsealed filing that notes data problems with the Botox sNDA, FDA contends that Allergan's First Amendment suit could allow companies to promote drugs that have not been shown to be effective.